Stockscreener 앱 받기
63.24
0.75%
0.47
시간 외 거래:
63.90
0.66
+1.04%
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
Why Structure Therapeutics Shares Are Surging Higher - TipRanks
Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace
Structure Therapeutics inks major GLP-1 licensing deal - MSN
Cantor Fitzgerald reiterates Structure Therapeutics stock rating at Overweight By Investing.com - Investing.com UK
Structure Therapeutics stock gets BMO Capital’s Outperform rating reaffirmed By Investing.com - Investing.com UK
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4%What's Next? - MarketBeat
Voya Investment Management LLC Sells 14,230 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - Defense World
Osaic Holdings Inc. Buys 31,972 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Down 3.3%Here's Why - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.2%Here's Why - MarketBeat
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up - Eastern Progress
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Finviz
Structure Therapeutics stock price target raised to $90 from $60 at H.C. Wainwright - Investing.com
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next? - Defense World
Avoiding Lag: Real-Time Signals in (GPCR) Movement - Stock Traders Daily
GPCRStructure Therapeutics Inc ADR Stock Price and Quote - Finviz
Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpStill a Buy? - MarketBeat
Why Structure Therapeutics Shares Are Under Pressure Now - TipRanks
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NOVN) and Pfizer (PFE) - The Globe and Mail
Structure Therapeutics begins phase 1 trial of oral obesity drug By Investing.com - Investing.com India
Structure Therapeutics begins phase 1 trial of oral obesity drug - Investing.com
New once-daily obesity pill enters first human tests using amylin biology - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 8.5%Should You Sell? - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00 - Defense World
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY) - The Globe and Mail
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Birchview Capital LP Buys Shares of 36,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics stock price target raised to $120 by Citizens - Investing.com South Africa
Structure Therapeutics (NASDAQ:GPCR) Raised to Hold at Wall Street Zen - MarketBeat
Structure Therapeutics Inc. (GPCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Federated Hermes Inc. Decreases Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics closes $747.5 million public offering - Investing.com
GPCR stock soars 102% on strong phase II obesity data for Aleniglipron - MSN
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by HighVista Strategies LLC - MarketBeat
Structure Therapeutics rises 101.6% - MSN
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? - sharewise.com
Structure Therapeutics Announces $650 Million Public Offering - The Globe and Mail
Structure Therapeutics’ Leap: What’s Sparking the Surge? - StocksToTrade
Structure Therapeutics Shares Surge on Promising Drug Results - TipRanks
Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result - Menafn
Structure Therapeutics prices upsized $650 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics prices upsized $650 million public offering - Investing.com
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants - GlobeNewswire Inc.
Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial - Finviz
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeWhat's Next? - MarketBeat
2.52%
0.07%
자본화:
|
볼륨(24시간):